Why the Pharmaxis (ASX:PXS) share price has rocketed up 48% today

The Pharmaxis share price has shot up by 47.73% this morning after positive news about the product pipeline and short term cash flow

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pharmaxis Ltd (ASX: PXS) today published a quarterly update in which the company reported three significant events. Consequently, the Pharmaxis share price has shot up 47.73% to 13 cents this morning. The pharmaceutical research company is working on inflammation and fibrosis. In addition it already has a portfolio of products at various stages of development and approval.

What's moving the Pharmaxis share price?

The company's announcement contained four very important issues for a drug research enterprise. One of which is linked to short term funding but all bode well for the Pharmaxis share price. 

First, the Food and Drug Administration (FDA) granted permission to progress its myelofibrosis drug, PXS‐5505, into a phase 1c/2 study. Myelofibrosis is a rare bone cancer. The company has moved quickly to contract Parexel to conduct the study which will start recruiting in Q1 2021.

Second, the FDA granted Pharmaxis orphan drug designation for PXS‐5505 in myelofibrosis. This means it is a treatment for a rare disease or condition. Or more succinctly, one that affects less than 200,000 persons in the US. This designation means the drug marketing application is not subject to a prescription drug user fee. 

Third, the Australian Government awarded Pharmaxis $1 million in funding for pre‐clinical drug. This was from the Biomedical Translation Bridge (BTB) program. It will significantly advance work on the company's drug discovery for the treatment of the devastating genetic disorder Duchenne Muscular Dystrophy (DMD).

In fact, the funding grant will take the company all the way to the start of phase 1 trials for this new drug candidate. Pharmaxis chief executive officer Garry Phillips said this was an example of the strategy to accelerate drug discovery until it could further define the commercial opportunity.

Bronchitol US FDA review

For the coming quarter, the company will be preparing to start the myelofibrosis study. However, there will also be considerable focus on the outcome of the Bronchitol NDA filed by US licensee Chiesi. The FDA have advised it has a 'goal action date' of 1 November 2020 which was yesterday. If successful, the company has a US$10m milestone payments attached to the approval and supply of launch stock to Chiesi.

Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Pharmaxis Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

asx share price represented by cartoon letters spelling the word FOMO
Share Market News

What did Macquarie's "FOMO Meter" reveal about the stock market in May?

Is the market getting frothy or is there still room to climb?

Read more »

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Dateline, DroneShield, Ora Banda, and Pilbara Minerals shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why BHP, Coronado Global, EBR Systems, and Whitehaven Coal shares are pushing higher today

These shares are ending the week on a positive note. Let's find out why.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why Macquarie expects this ASX 200 dividend stock to keep outperforming

Macquarie has tipped this ASX 200 dividend stock to outperform. Let’s find out why.

Read more »